Drug combo may help radioactive iodine work better in tough thyroid cancers
NCT ID NCT06440850
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 22 times
Summary
This study tests whether two targeted drugs, vemurafenib and cobimetinib, can make thyroid cancer cells more responsive to radioactive iodine therapy. About 21 adults with a specific gene mutation (BRAF V600E) and high-risk thyroid cancer will receive the drug combo before their first radioactive iodine treatment. The goal is to see if this approach leads to better cancer control with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND PAPILLARY CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.